- Home
- FCBC vs KROS Comparison
FCBC vs KROS Comparison
Compare FCBC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCBC
- KROS
- Stock Information
- Founded
- FCBC 1874
- KROS 2015
- Country
- FCBC United States
- KROS United States
- Employees
- FCBC N/A
- KROS N/A
- Industry
- FCBC Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- FCBC Finance
- KROS Health Care
- Exchange
- FCBC Nasdaq
- KROS Nasdaq
- Market Cap
- FCBC 590.1M
- KROS 565.0M
- IPO Year
- FCBC 1992
- KROS 2020
- Fundamental
- Price
- FCBC $31.63
- KROS $17.41
- Analyst Decision
- FCBC
- KROS Buy
- Analyst Count
- FCBC 0
- KROS 15
- Target Price
- FCBC N/A
- KROS $22.10
- AVG Volume (30 Days)
- FCBC 34.3K
- KROS 1.2M
- Earning Date
- FCBC 10-28-2025
- KROS 11-05-2025
- Dividend Yield
- FCBC 3.90%
- KROS N/A
- EPS Growth
- FCBC N/A
- KROS N/A
- EPS
- FCBC 2.68
- KROS 1.57
- Revenue
- FCBC $164,262,000.00
- KROS $246,718,000.00
- Revenue This Year
- FCBC $2.27
- KROS $6,657.47
- Revenue Next Year
- FCBC $11.13
- KROS N/A
- P/E Ratio
- FCBC $11.87
- KROS $11.09
- Revenue Growth
- FCBC 0.67
- KROS 37798.31
- 52 Week Low
- FCBC $31.35
- KROS $9.12
- 52 Week High
- FCBC $48.34
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- FCBC 36.08
- KROS 69.50
- Support Level
- FCBC $32.68
- KROS $16.74
- Resistance Level
- FCBC $33.67
- KROS $17.30
- Average True Range (ATR)
- FCBC 0.79
- KROS 0.62
- MACD
- FCBC -0.02
- KROS 0.19
- Stochastic Oscillator
- FCBC 7.24
- KROS 93.14
About FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.